Gene therapy for heart failure and cardiomyopathies

Rev Esp Cardiol (Engl Ed). 2023 Dec;76(12):1042-1054. doi: 10.1016/j.rec.2023.06.009. Epub 2023 Jul 26.
[Article in English, Spanish]

Abstract

Gene therapy strategies encompass a range of approaches, including gene replacement and gene editing. Gene replacement involves providing a functional copy of a modified gene, while gene editing allows for the correction of existing genetic mutations. Gene therapy has already received approval for treating genetic disorders like Leber's congenital amaurosis and spinal muscular atrophy. Currently, research is being conducted to explore its potential use in cardiology. This review aims to summarize the mechanisms behind different gene therapy strategies, the available delivery systems, the primary risks associated with gene therapy, ongoing clinical trials, and future targets, with a particular emphasis on cardiomyopathies.

Keywords: Cardiomyopathies; Enfermedades genéticas; Gene therapy; Genetic diseases; Miocardiopatías; Terapia génica.

Publication types

  • Review

MeSH terms

  • Cardiomyopathies* / genetics
  • Cardiomyopathies* / therapy
  • Genetic Therapy
  • Heart Failure* / genetics
  • Heart Failure* / therapy
  • Humans
  • Leber Congenital Amaurosis* / genetics
  • Leber Congenital Amaurosis* / therapy
  • Mutation